

François-Henri Reynaud appointed as Safe Orthopaedics' Chief Financial Officer

Eragny-sur-Oise, November 9, 2017, 8:00am CET – SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, today announces the appointment of François-Henri Reynaud as Chief Financial and Administrative Officer.

François-Henri has 13 years' experience in finance. For five years, he was initially involved in financing innovative business companies in a financial institution, before overseeing several corporate finance transactions (fund-raising transactions, mergers and acquisitions) as Chief Financial and Administrative Officer of companies in a variety of sectors including medical devices and renewable energies. His most recent appointment was at Global Bioenergies, a listed industrial biology company.

François-Henri Reynaud's main role will be to handle the Company's financial and administrative affairs, working closely with the Chief Executive Officer.

François-Henri Reynaud, Safe Orthopaedics' new Chief Financial and Administrative Officer, commented: *"It is a unique opportunity to join Safe Orthopaedics just as the Company has reported an increase in its third-quarter revenues of over 63% year-on-year and is expanding its business worldwide."*

Pierre Dumouchel, Chief Executive Officer and Co-founder of Safe Orthopaedics, added: *"Together with his expertise in finance, François-Henri's appointment as Chief Financial and Administrative Officer brings to the table his experience of establishing and building up international subsidiaries just as Safe Orthopaedics embarks on a new phase of expansion to accelerate its growth and business development"*.

Next financial release: full-year 2017 revenues, Monday, January 15, 2018 (after the market closes)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that aims to make spinal surgeries safer by using sterile implants and associated single-use instruments. Through this approach, these products eliminate all risk of contamination, reduce infection risks and facilitate a minimally-invasive approach for trauma and degenerative pathologies—benefiting patients. Protected by 17 patent families, the SteriSpine™ kits are CE-marked and FDA approved. The company is based at Eragny-sur-Oise (Val d'Oise department), and has 34 employees.

For more information, visit: www.SafeOrtho.com

Contacts

Safe Orthopaedics

François-Henri Reynaud
CFO

Tél.: +33 (0)1 34 21 50 00
investors@safeorthopaedics.com

NewCap

Julien Perez / Valentine Bouchot
Investor Relations

Nicolas Merigeau
Media Relations

Tél.: +33 (0)1 44 71 94 94
SafeOrtho@newcap.eu

SAFOR
LISTED
EURONEXT